Explore every episode of the podcast Peptides Weekly

Peptides Weekly Unapproved peptides could reach temporary sale while treatment claims are still not fully safety tested. What You Need to Know: Unapproved peptides could reach temporary sale while treatment claims are still not fully safety tested. Political Wire, quoting The Washington Post, describes a drafting process for previously restricted peptides, not a completed approval and not a patient trial. ... Sources: washingtonpost.com · stocktwits.com · ascopost.com · amp.sacbee.com · foodnavigator.com AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. If this episode was useful, a rating or a short review on Apple Podcasts or Spotify is how the next listener finds the show — and following it in your app means the next episode is there when you are. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

Peptides Weekly Nail detachment was over four times more common in people using GLP-1 drugs. What You Need to Know: A controlled study found nail detachment more than four times as often among people using GLP-1 drugs. The same week brought a muscle-loss trial beside semaglutide, a randomized look at how semaglutide meets the kidney, and two reminders that a population trend and a protein-design paper are not treatment results. ... Sources: medicalxpress.com · reuters.com · nature.com · t.co AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

Peptides Weekly Nearly one in six children taking GLP-1 drugs show nutritional deficiencies in a new study. What You Need to Know: A retrospective analysis found nutritional deficiencies in almost 17 percent of children prescribed GLP-1 receptor agonists for weight loss or diabetes. The finding comes from claims data and highlights a measurable gap in monitoring for younger patients. ... Sources: sciencedaily.com · yaledailynews.com · euractiv.com · velo.outsideonline.com · sciencedirect.com · europepmc.org AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.

Peptides Weekly Phase 3 results for an investigational amylin peptide medicine in diabetes and obesity were released this week. What You Need to Know: Novo Nordisk reported new phase 3 data on an amylin-based candidate. A pair of randomized trials found oral semaglutide did not slow progression in mild Alzheimer’s disease. ... AI Disclosure: This podcast is curated by Patrick but uses AI-generated voice synthesis for audio production. 📝 Full show notes, transcript & sources: read the episode page 🌐 Part of the Nerra Network — explore every show at nerranetwork.com.